Gero Raises $17M to Build a Physics Model That Predicts How Fast You Age

Gero's $17 million funding round is notable not just for the money but for what it represents: a growing conviction that aging can be modeled mathematically, not just observed biologically. The company's platform is built on the idea that aging follows quantifiable physical laws detectable within large-scale human health data. That proposition puts Gero at the frontier of a field sometimes called gerophysics — an emerging discipline applying statistical physics and dynamical systems theory to aging biology.

At the core of Gero's framework, developed over more than a decade by CEO Dr. Peter Fedichev and collaborators including Dr. Jan Gruber at the National University of Singapore, is the concept that aging represents a gradual loss of physiological resilience. This loss leaves measurable signatures in longitudinal health data — signatures that AI models, trained on approximately 10 million data points, are designed to detect and interpret. The goal is not just to identify that someone is aging, but to understand the rate at which they are aging and why.

This shift from description to prediction matters enormously for longevity science. Traditional geroscience has catalogued hallmarks and biomarkers with increasing precision, but catalogues are not explanations. Gero's physics-inspired approach asks a deeper question: what rules govern the pace of biological aging? The naked mole-rat — an animal that ages far more slowly than its size would predict — is invoked as proof that aging rates are biologically negotiable. Evolution has demonstrated slower aging is possible; science now needs to decode the mechanism.

The Chugai Pharmaceutical partnership, with up to $250 million in milestones, suggests that major pharma sees commercial value in predictive aging platforms, potentially accelerating drug development targeting aging rate rather than individual diseases.

Caveats apply: this is a funding and platform story, not a clinical trial result. The framework remains largely theoretical and computational at this stage, with therapeutic validation still ahead.